SCHEMBL16102453

SCHEMBL16102453

COc1ccc(C(=O)Nc2nnc(-c3ccccc3)s2)cc1[N+](=O)[O-]

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.65
TDP1 Q9NUW8 2/20 0.65
CYP3A4 P08684 1/20 0.65
TSHR P16473 1/20 0.65
NPC1 O15118 5/20 0.62
RAB9A P51151 4/20 0.62
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
RXFP1 Q9HBX9 1/20 0.62
POLB P06746 2/20 0.57
NOX1 Q9Y5S8 3/20 0.57
MAPT P10636 2/20 0.56
WNT3A P56704 1/20 0.56
LMNA P02545 1/20 0.55
GAA P10253 1/20 0.55
ABCB1 P08183 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16102452 0.86 WNT3A (0.58) ALDH1A1TDP1CYP3A4TSHRNPC1
SCHEMBL16102364 0.86 ALDH1A1 (0.62) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL16101891 0.85 WNT3A (0.59) ALDH1A1CYP3A4NPC1RAB9AMEN1
SCHEMBL16119638 0.84 ALDH1A1 (0.62) ALDH1A1CYP3A4NPC1RAB9AMEN1
SCHEMBL16101712 0.83 NPC1 (0.67) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL16101372 0.82 NPC1 (0.55) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL16119726 0.81 WNT3A (0.55) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL16102486 0.81 RAB9A (0.57) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL16098533 0.80 ALDH1A1 (0.86) ALDH1A1TDP1CYP3A4TSHRRAB9A
SCHEMBL16100709 0.80 WNT3A (0.59) ALDH1A1CYP3A4NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10130633-B2 Compounds BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-11-20 US disclosed
EP-2976327-B1 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS Bayer Pharma AG (DE) 2017-06-21 EP disclosed
EP-2976327-B1 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS Bayer Pharma AG (DE) 2017-06-21 EP disclosed
US-20160263122-A1 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-09-15 US disclosed
EP-2976327-A2 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS Bayer Pharma Aktiengesellschaft (DE) 2016-01-27 EP disclosed
WO-2014147021-A2 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-25 WO disclosed
WO-2014147021-A2 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160263122-A1 NOVEL COMPOUNDS NAT1, AADAC, CBR3 ALDH1A1 264/4885TDP1 4213/4885CYP3A4 131/4885
US-10130633-B2 Compounds AADAC, NAT1, CBR3 ALDH1A1 277/4885TDP1 4346/4885CYP3A4 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.